Pharma BD Deal Intelligence
Phase 1 siRNA in-license expanding GSK cardiometabolic reach
Full analysis, sources & comparables →GSK goes beyond weight-loss with $1B deal for Chinese siRNA specialist SiranBio (SA-030, ALK7).
GSK bolts on siRNA drug from China's SiranBio in $1bn deal.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
On May 6, 2026, GSK and Suzhou Siran Biotechnology (SiranBio) announced an exclusive worldwide license agreement (excluding mainland China, Hong Kong, Macau and Taiwan) for SA-030 (SA030), a potentially first-in-disease, long-acting small interfering RNA (siRNA) oligonucleotide targeting activin receptor-like kinase 7 (ALK7) for metabolic and vascular (cardiometabolic) disease, with an obesity/abdominal-fat-reduction angle. GSK pays $55 million upfront and up to ~$1.005 billion in development, regulatory, and commercial milestones, plus tiered royalties. SiranBio will advance SA-030 through completion of Phase 1, after which GSK assumes development, regulatory filings, and commercialization outside the excluded regions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Suzhou Siran Biotechnology Co., Ltd. (this deal) | 2026 | $1.1B | 55 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2026 deals · GSK plc deals · Cardiovascular deals